[{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"357b4d1c-0cfa-4162-a300-61812b45530e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05602194","created_at":"2022-11-02T14:56:42.944Z","updated_at":"2025-02-25T15:20:06.675Z","phase":"Phase 3","brief_title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","source_id_and_acronym":"NCT05602194","lead_sponsor":"Children's Oncology Group","biomarkers":" CRLF2 • PNPLA3 • SOD2","pipe":"","alterations":" ","tags":["CRLF2 • PNPLA3 • SOD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2025-02-12"},{"id":"92f3f7c6-e282-4c02-a649-a3d88aca09fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04953780","created_at":"2024-03-18T13:21:29.779Z","updated_at":"2024-07-02T16:35:14.325Z","phase":"Phase 1","brief_title":"2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML","source_id_and_acronym":"NCT04953780","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" MCL1 • BCL2L1","pipe":" | ","alterations":" BCL2 expression","tags":["MCL1 • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • Asparlas (calaspargase pegol-mknl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/27/2021","start_date":" 09/27/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-18"},{"id":"8d2fd6b3-99fe-4b7c-a171-d1e7a5b2b2a9","acronym":"ENFORCE","url":"https://clinicaltrials.gov/study/NCT01810705","created_at":"2021-01-18T08:01:47.336Z","updated_at":"2024-07-02T16:36:16.865Z","phase":"Phase 2b","brief_title":"GRASPA Treatment for Patients With Acute Myeloblastic Leukemia","source_id_and_acronym":"NCT01810705 - ENFORCE","lead_sponsor":"ERYtech Pharma","biomarkers":" ASNS","pipe":"","alterations":" ","tags":["ASNS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 123","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 11/10/2017","primary_completion_date":" 11/10/2017","study_txt":" Completion: 11/10/2017","study_completion_date":" 11/10/2017","last_update_posted":"2022-02-21"},{"id":"98093373-bb38-49b2-ab54-0f82bc015fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01523808","created_at":"2021-10-15T22:53:09.067Z","updated_at":"2024-07-02T16:36:22.983Z","phase":"Phase 1","brief_title":"Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT01523808","lead_sponsor":"ERYtech Pharma","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 03/01/2011","primary_completion_date":" 03/01/2011","study_txt":" Completion: 03/01/2011","study_completion_date":" 03/01/2011","last_update_posted":"2021-10-15"},{"id":"dd0cb067-9e6d-4806-b78d-9c53942826a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02195180","created_at":"2021-01-18T10:15:55.266Z","updated_at":"2024-07-02T16:37:08.554Z","phase":"Phase 2","brief_title":"Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","source_id_and_acronym":"NCT02195180","lead_sponsor":"ERYtech Pharma","biomarkers":" ASNS","pipe":"","alterations":" ","tags":["ASNS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • Graspa (eryaspase)"],"overall_status":"Completed","enrollment":" Enrollment 141","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 11/01/2017","study_completion_date":" 11/01/2017","last_update_posted":"2018-07-27"}]